Impact of glycoprotein VI and platelet adhesion on atherosclerosis--a possible role of fibronectin.
Glycoprotein VI (GPVI) mediates binding of platelets to subendothelial collagen during acute arterial thrombosis. GPVI interactions with the activated atherosclerotic vascular endothelium during early atherosclerosis, however, are not well understood. In ApoE-/- mice, platelet adhesion to atherosclerotic arteries was increased, as measured by intravital microscopy. This platelet adhesion was significantly inhibited by IV injection of GPVI-Fc (1 mg/kg body weight). Atherosclerosis in ApoE-/- mice was attenuated both after 7 and 10 weeks of treatment with the anti-GPVI antibody JAQ1 (2 mg/kg body weight i.p. twice weekly). Binding of GPVI-Fc (1 mg/kg IV) occurred to deeper layers, but also to the luminal site of plaques in atherosclerotic rabbits, but not to the vessel wall of healthy littermates. Gene transfer of GPVI-Fc to the carotid vascular wall significantly attenuated athero-progression and endothelial dysfunction in atherosclerotic rabbits in vivo. Specific binding of the soluble GPVI receptor (GPVI-Fc) to fibronectin was found in vitro to coated ELISA plates. Platelet adhesion to fibronectin was significantly inhibited both by GPVI-Fc and by the anti-GPVI antibody 5C4 ex vivo in flow chamber experiments. GPVI plays a role in platelet adhesion to atherosclerotic endothelium in the absence of plaque rupture. Inhibition of GPVI both via GPVI-Fc and anti-GPVI-antibodies results in protection against atherosclerosis in both cholesterol-fed rabbits and ApoE-/- mice. This novel mechanism of GPVI-mediated platelet adhesion-possibly via fibronectin-could relevantly contribute to platelet-triggered atheroprogression.
Bültmann
Andreas
A
Corimmun GmbH, Martinsried, Germany.
Li
Zhongmin
Z
Wagner
Silvia
S
Peluso
Mario
M
Schönberger
Tanja
T
Weis
Carla
C
Konrad
Ildiko
I
Stellos
Konstantinos
K
Massberg
Steffen
S
Nieswandt
Bernhard
B
Gawaz
Meinrad
M
Ungerer
Martin
M
Münch
Götz
G
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001057:Apolipoproteins E / Q000502:physiology; D050197:Atherosclerosis / Q000378:metabolism / Q000473:pathology*; D016466:CHO Cells; D002339:Carotid Arteries / Q000378:metabolism / Q000473:pathology; D006224:Cricetinae; D003412:Cricetulus; D004730:Endothelium, Vascular / Q000378:metabolism* / Q000473:pathology; D005353:Fibronectins / Q000378:metabolism*; D018014:Gene Transfer Techniques; D049452:Green Fluorescent Proteins; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015539:Platelet Activation; D010973:Platelet Adhesiveness / Q000502:physiology*; D010980:Platelet Membrane Glycoproteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D011817:Rabbits
D000911:Antibodies, Monoclonal; D001057:Apolipoproteins E; D005353:Fibronectins; D010980:Platelet Membrane Glycoproteins; C485184:enhanced green fluorescent protein; C098341:platelet membrane glycoprotein VI; D049452:Green Fluorescent Proteins